Skip to Content

Shannon N. Westin, MD, MPH, FACOG

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

 I am a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic cancers. My background in public health, with a focus on clinical investigation and epidemiology, has provided me with a clear understanding of the study design and validation techniques which are essential to the study of these topics. I am principal investigator of several novel treatment trials for endometrial cancer as well as a phase 1 trial of agents relevant to ovarian cancer.    As part of the Stand Up to Cancer collaboration, I serve as the MD Anderson principal investigator for a trial of MK-2206, an AKT inhibitor, in recurrent endometrial cancer. This trial incorporates a novel biomarker-driven design, utilizing stratification by PIK3CA mutation status.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman Pressler St.
Unit Number: 1362
Houston, TX 77030
Room Number: CPB6.3279
Fax: 713-792-7586

Education & Training

Degree-Granting Education

2002 University of Florida College of Medicine, Gainesville, FL, MD, Medicine
1998 University of Miami, Coral Gables, FL, BS, Cum Laude, Psychobiology

Postgraduate Training

7/2006-6/2010 Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Diane Bodurka, M.D.
7/2002-6/2006 Clinical Residency, Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC, Robert Strauss, M.D.

Board Certifications

2012 American Board of Obstetrics and Gynecology, Diplomate, Obstetrics and Gynecology

Selected Publications

Peer-Reviewed Original Research Articles

1. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: Impact of treatment on health and well-being. J Cancer Surviv 10(2):261-70, 4/2016. e-Pub 8/2015. PMCID: PMC4744585.
2. Westin SN, Randall L. The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topics. Gynecol Oncol 140(3):377-80, 3/2016. e-Pub 1/2016. PMID: 26807487.
3. Darin MC, Gómez-Hidalgo NR, Westin SN, Soliman PT, Escobar PF, Frumovitz M, Ramirez PT. Role of indocyanine green (ICG) in sentinel node mapping in gynecologic cancer: Is fluorescence imaging the new standard? J Minim Invasive Gynecol 23(2):186-93, 2/2016. e-Pub 10/2015. PMID: 26518716.
4. Yang JY, Werner HM, Li J, Westin SN, Lu Y, Halle MK, Trovik J, Salvesen HB, Mills GB, Liang H. Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer. Clin Cancer Res 22(2):513-23, 1/2016. e-Pub 7/2015. PMCID: PMC4715969.
5. Fleming ND, Soliman PT, Westin SN, Reis RD, Munsell M, Klopp AH, Frumovitz M, Nick AM, Schmeler K, Ramirez PT. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer 25(8):1437-44, 10/2015. e-Pub 9/2015. PMCID: PMC4581897.
6. Ho JC, Allen PK, Jhingran A, Westin SN, Lu KH, Eifel PJ, Klopp AH. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol 139(1):40-6, 10/2015. e-Pub 7/2015. PMID: 26193429.
7. Subbiah V, Wagner MJ, McGuire MF, Sarwari NM, Devarajan E, Lewis VO, Westin S, Kato S, Brown RE, Anderson P. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Oncotarget. e-Pub 10/2015. PMID: 26510912.
8. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol 9(8):1694-703, 10/2015. e-Pub 5/2015. PMCID: PMC4584169.
9. Arms RG, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol 138(3):727-30, 9/2015. e-Pub 7/2015. PMID: 26197762.
10. dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, Munsell MF, Ramirez PT. Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Int J Gynecol Cancer 25(7):1292-9, 9/2015. PMCID: PMC4549160.
11. Fleming ND, Frumovitz M, Schmeler KM, dos Reis R, Munsell MF, Eifel PJ, Soliman PT, Nick AM, Westin SN, Ramirez PT. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol 136(1):48-53, 1/2015. e-Pub 11/2014. PMID: 25451695.
12. Holman LL, Ren Y, Westin SN. Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC Cancer 15:728, 2015. e-Pub 10/2015. PMCID: PMC4609077.
13. Costales AB, Schmeler KM, Broaddus R, Soliman PT, Westin SN, Ramirez PT, Frumovitz M. Clinically Significant Endometrial Cancer Risk Following a Diagnosis of Complex Atypical Hyperplasia. Gynecol Oncol 135(3):451-4, 12/2014. e-Pub 10/2014. PMCID: PMC4268403.
14. Ulm MA, Fleming ND, Rallapali V, Munsell MF, Ramirez PT, Westin SN, Nick AM, Schmeler KM, Soliman PT. Position-related injury is uncommon in robotic gynecologic surgery. Gynecol Oncol 135(3):534-8, 12/2014. e-Pub 10/2014. PMCID: PMC4268144.
15. Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, Schmeler KM, Klopp AH, Fleming ND. Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol 135(3):455-61, 12/2014. e-Pub 10/2014. PMID: 25449308.
16. Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin SN, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer 111(10):1932-44, 11/2014. e-Pub 10/2014. PMCID: PMC4229637.
17. Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, Ramondetta LM, Bodurka DC, Ramirez PT, Soliman PT. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol 134(3):546-51, 9/2014. e-Pub 7/2014. PMCID: PMC4160382.
18. Jones N, Fleming ND, Nick AM, Munsell MF, Rallapalli V, Westin SN, Meyer LA, Schmeler KM, Ramirez PT, Soliman PT. Conversion from robotic surgery to laparotomy: A case-control study evaluating risk factors for conversion. Gynecol Oncol 134(2):238-42, 8/2014. e-Pub 6/2014. PMCID: PMC4125462.
19. Slaughter KN, Frumovitz M, Schmeler KM, Nick AM, Fleming ND, Reis RD, Munsell MF, Westin SN, Soliman PT, Ramirez PT. Minimally invasive surgery for endometrial cancer: Does operative start time impact surgical and oncologic outcomes? Gynecol Oncol 134(2):248-52, 8/2014. e-Pub 6/2014. PMID: 24945591.
20. Rauch GM, Kaur H, Choi H, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Marcal LP. Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer. Radiographics 34(4):1082-98, Jul-Aug, 7/2014. PMCID: PMC4307629.
21. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to Mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer 24(4):713-7, 5/2014. PMCID: PMC4039301.
22. Pakish J, Soliman PT, Frumovitz M, Westin SN, Schmeler KM, Reis RD, Munsell MF, Ramirez PT. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol 132(2):366-71, 2/2014. e-Pub 12/2013. PMID: 24361579.
23. Huang M, Iglesias DA, Westin SN, Fellman B, Urbauer D, Schmeler KM, Frumovitz M, Ramirez PT, Soliman PT. Pelvic exenteration: Impact of age on surgical and oncologic outcomes. Gynecol Oncol 132(1):114-8, 1/2014. e-Pub 11/2013. PMID: 24262877.
24. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One 9(2):e89388, 2014. e-Pub 2/2014. PMCID: PMC3929689.
25. Tang C, Fontes Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience 1(1):5-13, 2014. e-Pub 12/2013. PMCID: PMC4295762.
26. Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, Ross JS, Stephens PJ, Palmer GA, Ali SM. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol 7(1):8, 2014. e-Pub 1/2014. PMCID: PMC3896681.
27. Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR. Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer. Curr Pharm Des 20(11):1655-63, 2014. e-Pub 7/2013. PMCID: PMC3895501.
28. Soliman PT, Iglesias D, Munsell MF, Frumovitz M, Westin SN, Nick AM, Schmeler KM, Ramirez PT. Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecol Oncol 131(3):730-3, 12/2013. e-Pub 9/2013. PMCID: PMC3856555.
29. Clark LH, Soliman PT, Odetto D, Munsell MF, Schmeler KM, Fleming N, Westin SN, Nick AM, Ramirez PT. Incidence of trocar site herniation following robotic gynecologic surgery. Gynecol Oncol 131(2):400-3, 11/2013. e-Pub 8/2013. PMID: 23988416.
30. Huang M, Djordjevic B, Yates MS, Urbauer D, Sun C, Burzawa J, Daniels M, Westin SN, Broaddus R, Lu K. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer 119(16):3027-33, 8/2013. e-Pub 6/2013. PMID: 23760948.
31. Urh A, Soliman PT, Schmeler KM, Westin SN, Frumovitz M, Nick AM, Fellman B, Urbauer DL, Ramirez PT. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol 129(3):580-5, 6/2013. e-Pub 2/2013. PMID: 23480870.
32. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 31(1):213-29, 2/2013. e-Pub 6/2012. PMID: 22661305.
33. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-9, 11/2012. e-Pub 10/2012. PMCID: PMC3483541.
34. Iglesias DA, Westin SN, Rallapalli V, Huang M, Fellman B, Urbauer D, Frumovitz M, Ramirez PT, Soliman PT. The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol Oncol 125(2):336-42, 5/2012. e-Pub 1/2012. PMID: 22261299.
35. Berger JL, Westin SN, Fellman B, Rallapali V, Frumovitz M, Ramirez PT, Sood AK, Soliman PT. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol 125(1):252-5, 4/2012. e-Pub 12/2011. PMID: 22166844.
36. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. J Clin Oncol 30(8):777-82, 3/2012. e-Pub 1/2012. PMCID: PMC3295566.
37. Covert WM, Westin SN, Soliman PT, Langley GD. The role of mucoregulatory agents after continence-preserving urinary diversion surgery. Am J Health Syst Pharm 69(6):483-6, 3/2012. PMID: 22382478.
38. Brown AJ, Westin SN, Broaddus RR, Schmeler K. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 119(2 Pt 2):423-6, 2/2012. PMCID: PMC3266511.
39. Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: Challenges and opportunities. Cancer Biol Ther 13(1):1-13, 1/2012. e-Pub 1/2012. PMCID: PMC3335980.
40. Soliman PT, Frumovitz M, Sun CC, Dos Reis R, Schmeler KM, Nick AM, Westin SN, Brown J, Levenback CF, Ramirez PT. Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol 123(2):333-6, 11/2011. e-Pub 8/2011. PMID: 21872911.
41. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 117(12):2659-67, 6/2011. e-Pub 12/2010. PMID: 21656744.
42. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121(2):358-63, 5/2011. e-Pub 1/2011. PMID: 21276604.
43. Cantrell LA, Westin SN, Van Le L. The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer 117(6):1220-6, 3/2011. e-Pub 11/2010. PMID: 21381011.
44. Kincey J, Westin SN, Zhao B, Curtis MG, Ramondetta L. Surgical removal of a gigantic abdominal mass: A multidisciplinary approach. Obstet Gynecol 117(2 Pt 2):508-12, 2/2011. PMID: 21252807.
45. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther 8(22):2126-35, 11/2009. e-Pub 11/2009. PMCID: PMC2872176.
46. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/2009. PMCID: PMC2680417.
47. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 200(2):186.e1-8, 2/2009. PMCID: PMC2880878.
48. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 26(36):5965-71, 12/2008. e-Pub 11/2008. PMCID: PMC2645115.
49. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111(1):132-6, 10/2008. e-Pub 8/2008. PMID: 18684498.
50. Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL, Sun CC, Ramondetta LM. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol 111(3):747-51, 3/2008. PMID: 18310380.
51. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. Gynecol Oncol 107(1):71-4, 10/2007. e-Pub 6/2007. PMID: 17599395.
52. Westin SN, Skinner EN, Jonsson Funk M, Gehrig PM, Van Le L. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer. Gynecol Oncol 105(2):414-7, 5/2007. e-Pub 1/2007. PMID: 17250880.

Invited Articles

1. Liu J, Westin SN,. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 141(1):65-71, 4/2016. PMCID: PMC4808566.
2. Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother 14(16):2171-2182, 11/2013. e-Pub 8/2013. PMID: 23937415.
3. Westin SN, Mills GB, Myers AP. Repurposing the pap smear: one step closer to gynecologic cancer screening. Sci Transl Med 5(167):167ps1, 1/2013. PMID: 23303602.
4. Tierney B, Westin SN, Schlumbrecht MP, Ramirez PT. Early cervical neoplasia: advances in screening and treatment modalities. Clin Adv Hematol Oncol 8(8):547-55, 8/2010. PMID: 20966891.
5. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 8(7):1159-67, 7/2008. PMID: 18588460.
Other Articles
1. Westin SN. The obstetric forceps: shrouded in mystery. Obstet Gynecol Surv 61(6):357-8, 6/2006. PMID: 16719940.
2. Neville S. Ignaz Semmelweis. Primary Care Update Obstetrics/Gynecology 20:1-2, 2003.


1. Klopp AH, Westin SN. A phase III randomized trial comparing patient reported toxicity and quality of life (QOL) during pelvic IMRT as compared to conventional Ratiotherapy. American Society for Radiation Oncology (ASTRO) Annual Meeting, 9/2016.
2. Westin SN, Sun CC, Broaddus RR, Pal N, Woodall, Urbauer DL, Ramondetta L, Lu KH, Coleman RL, Bodurka DC. Challenging the Paradigm of Progesterone-Only Therapy for Early Endometrial Cancer: Results of a Prospective Trial of the Levonorgestrel Intrauterine System. 47th Annual Meeting of the Society of Gynecologic Oncologists (SGO), 3/2016.
3. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore K, Mathews C, Jain A, Modesitt, Schilder R, Aghajanian C. Limited Access Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. 47th Annual Meeting of the Society of Gynecologic Oncologists (SGO), 3/2016.
4. Banerji U, Dean EJ, Perez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Davies B, Elvin P, Lawrence P, Yates J, Ambrose H, Rugman P, Foxley A, Salim S, Casson E, Lindemann JP, Schellens JH. A parmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. J Clin Oncol(33), 6/2015.
5. Kopetz S, Litzenburger B, Kinua W, Sajan B, Subbiah V, Zinner R, Wheeler JJ, Hong DS, Tsimberidou AP, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol(33), 6/2015.
6. Oughli HA, Balakrishnan N, Munsell MF, Shiozaki T, Frumovitz MM, Soliman PT, Schmeler KM, Ramirez PT, Nick AM, O'Brien BJ, Westin SN. Paraneoplastic neurologic syndrome in ovarian carcinoma. Gynecologic Oncology 137(1):181, 4/2015.
7. Holman LL, Dockery LE, Soliman PT, Pal N, Broaddus R, Shiozaki T, Fleming ND, Munsell MF, Lu KH, Westin SN. Platinum-free interval is a predictor of survival for recurrent, advanced-stage uterine papillary serous carcinoma. Gynecologic Oncology 137(1):159-160, 4/2015.
8. Westin SN, Castaneda M, Pal N, Urbauer D, JankuF, Wheler J, Piha-Paul S, Naing A, Tsimberidou A, Fu S, Hong D, Subbiah V, Zinner R, Karp D, Coleman R, Moulder S, Kurzrock R. Phase I trial of carboplatin, bevacizumab, and temsirolimus in advanced solid tumors. 19th International Meeting of the European Society of Gynaecological Oncology (ESGO) (#717), 2015.
9. Matulonis U, Wulf GM, Birrer MJ, Westin SN, Quy P, Bell-McGuinn KM, Lasonde B, Whalen C, Aghajanian C, Solit DB, Mills GB, Cantley L, Winer EP. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). J Clin Oncol(32):Abstract # 2510 (#2510), 6/2014.
10. Konstantinopoulos P, Makker V, Barry WT, Liu J, Horowitz NS, Birrer MJ, Doyle LA, Berlin ST, Whalen C, Hummelen PV, Coleman RL, Aghajanian C, Mills GB, Matulonis U, Westin SN, Myers AP. Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. J Clin Oncol(32):Abstract # 5515 (#5515), 6/2014.
11. Soliman PT, Broaddus R, Westin SN, Iglesias DA, Burzawa JK, Zhang Q, Munsell MF, Schmandt R, Ramondetta LM, Lu KH, Bae-Jump VL. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. J Clin Oncol(32):Abstract # 5510 (#5510), 6/2014.
12. Brown, AJ, Huang M, Sun CC, Zaid TM, Balakrishnan N, Mhadgut H, Lu HK, Westin SN, Bodurka DC. Benefits of neoadjuvant chemotherapy in ovarian, primary peritoneal, or fallopian tube carcinoma. J Clin Oncol(31):Abstract # 5580, 6/2013.
13. Huang M, Sun CC, Westin SN, Bodurka DC. Hormone replacement therapy (HRT) prescribing patterns among gynecologic oncologists. J Clin Oncol(31):Abstract # 20637, 6/2013.
14. Holman LL, Iglesias PT, Soliman NP, Klopp A, Broaddus R, Ayeni T, Fleming ND, Munsell MF, Lu KH, Westin SN. Long-term survival in advanced-stage uterine papillary serous carcinoma. J Clin Oncol(31):Abstract # 5596, 6/2013.
15. Soliman PT, Sun CC, Westin SN, Ramondetta LM, Bodurka DC, Bradford A. Longitudinal quality of life (ZOL0 and sexual functioning in women undergoing pelvic exenteration for gynecologic malignancies. J Clin Oncol(31):Abstract # 5608, 6/2013.
16. Zaid TM, Huang M, Brown AJ, Balakrishnab N, Mhadgut H, Pal N, Wei C, Broaddus R, Bodurka DC, Lu KH, Westin SN. Pathologic distribution of disease at the time of interval debulking versus primary tumor reduction in women with primary peritoneal, ovarian, or Fallopian tube carcinoma. J Clin Oncol(31):Abstract # 5584, 6/2013.
17. Westin SN, Smart ML, Pal N, Urbauer DL, Janku F, Wheler JJ, Piha-Paul SA, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Zinner R, Subbiah V, Culotta KS, Lu KH, Coleman RL, Kurzrock R. Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. J Clin Oncol(31):Abstract # 2611, 6/2013.
18. Myers AP, Broaddus R, Makker, V, Konstantinopoulos PA, Drapkin R, Horowitz NS, Liu J, Hummelen PV, Meric-Bernstam F, Birrer MJ, Doyle A, Coleman RL, Aghajanian C, Mills GB, Cantley L, Matulonis UA, Westin SN. Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). J Clin Oncol(31):Abstract # 5524, 6/2013.
19. *Ju Z, *Westin SN, Broaddus R, Li J, Pal N, Lu KH, Coleman RL, Klempner S, Cantley L, Mills GB, Myers AP (*First Authors). PTEN loss as a context-dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. J Clin Oncol(31):Abstract # 5521, 6/2013.
20. Iglesias DA, Holman LL, Westin SN Fellman B, Schmeler KM, Ramirez PT, Frumovitz MM, Lu KH, Soliman PT. Recurrence and survival outcomes following adjuvant therapy for early-stage uterine serous carcinoma (USC). J Clin Oncol(31):Abstract # e16556, 6/2013.
21. Ramirez P, Broaddus R, Frumovitz M, Schmeler K, Westin SN, Munsell M, Matamoros A, Quang T, Dobbs J, Richards-Kortum R. A phase II study of multimodal optical imaging to evaluate tumor margins for potential use in conservative, uterine-sparing surgery for women with endometrial cancer. Gynecologic Oncology 130 (1):e80, 3/2013.
22. Holman, L, Soliman P, Pal N, Balakrishnan N, Klopp a, Broaddus R, Fleming N, Munsell M, Lu K, Westin SN. Importance of platinum sensitivity and treatment modality in advanced-stage uterine papillary serous carcinoma. Gynecologic Oncology 130 (1):e79, 3/2013.
23. Soliman P, Sun C, Westin SN, Fleming N, Schmeler K, Nick A, Ramirez P. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecologic Oncology 130 (1), 3/2013.
24. Westin SN, Sun C, Pal N, Janku F, Tsimberidou A, Falchook G, Hong D, Lu K, Coleman R. KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenomenal outcome in primary disease. Gynecologic Oncology 130 (1):e162, 3/2013.
25. Holman L, Soliman P, Pal N, Mhadgut H, Klopp A, Broaddus R, Fleming, Munsell M, Lu K, Westin SN. Neoadjuvant chemotherapy in stage IV uterine papillary serous carcinoma. Gynecologic Oncology 130 (1):e82, 3/2013.
26. Soliman P, Broaddus R, Westin SN, Iglesias D, Munsell M, Scmandt R, Celestino J, Burzawa J, Lu K. Phase 0 study: Prospective evaluation for the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer. Gynecologic Oncology 130 (1):e13, 3/2013.
27. Tung C, Westin SN, Sun C, Lacour R, Meyer L, Schlumbrecht M, Bodurka D. Sleep disturbances: A critical issue among gynecologic cancer survivors. Gynecologic Oncology 130 (1):e7, 3/2013.
28. Bradford, A, Soliman P, Westin SN, Lang K, Anderson S, Ramondetta L. Symptoms of posttraumatic stress disorder in women who have undergone exenterative pelvic surgery for treatment of gynecologic malignancy. Gynecologic Oncology 130 (1):e30-e31, 3/2013.
29. Carroll, A, Ramirez P, Westin SN, Soliman P, Munsell M, Nick A, Schmeler K, Frumovitz M, Fleming N. Uterine adenosarcoma: A closer look at a rare disease. Gynecologic Oncology 130 (1):e152, 3/2013.
30. Bruegl A, Westin SN, Djordjevic B, Broaddus R. Common screening criteria for Lynch syndrome: Who are we missing?. Gynecologic Oncology 125(1):S33, 3/2012.
31. Westin SN, Sun C, Broaddus R, Pal N, Nath V, Urbauer D, Schmeler K, Lu K, Bodurka D, Johnston T. Prospective phase II trial of the Levonorgestrel Intrauterine System (Mirena) to treat complex atypical hyperplasia and grade 1 endometrioid endometrial cancer. Gynecologic Oncology 125(1):S9, 3/2012.
32. Iglesias D, Munsell M, Frumovitz M, Westin SN, Nick A, Schmeler K, Ramirez P, Soliman P. Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecologic Oncology 125(1):S125, 3/2012.
33. Huang M, Westin SN, Iglesias D, Fellman B, Urbauer D, Frumovitz M, Ramirez P, Soliman P. Surgical outcomes and disease recurrence following pelvic exenteration: Does age matter?. Gynecologic Oncology 125(1):S77, 3/2012.
34. Iglesias D, Westin SN, Rallapalli V, Huang M, Fellman B, Urbauer D, Frumovitz M, Ramirez P, Soliman P. The effect of body mass index (BMI) on surgical outcomes and disease recurrence following pelvic exenteration. Gynecologic Oncology 125(1):S125, 3/2012.
35. Bruegl AS, Djordjevic B, Westin SN, Soliman PT, Brandt AC, Daniels MS, Lu KH, Broaddus R. An alternative approach to identify women at risk for colorectal cancer. J Clin Oncol 30(16):#1513, 2012.
36. Schlumbrecht M, Sun C, Westin SN, Zandstra F, Tung C, Denton K, Rhodes H, Garcia E, Levenback C, Bodurka D. Lifestyle modification in cervical cancer survivors: An ongoing need. Gynecologic Oncology I20(1):S109, 3/2011.
37. Huang M, Westin SN, Sun C, Meyer L, Tung C, Urbauer D, Bodurka D. Menopausal symptoms and use of hormone replacement therapy: The gynecologic cancer survivors' perspective. Gynecologic Oncology I20(1):S82, 3/2011.
38. Westin SN, Rallapalli V, Urbauer D, Frumovitz M, Ramondetta L, Bodurka D, Ramirez P, Soliman P. Overall survival after pelvic exenteration for recurrent or persistent cervical cancer. Gynecologic Oncology I20(1):S111, 3/2011.
39. Huang M, Djordjevic B, Urbauer D, Westin SN, Sun CC, Burzawa JK, Meyer L, Bodurka DC, Broaddus R, Lu KH. Molecular analysis of endometrial pathogenesis in Lynch syndrome. J Clin Oncol 29:#5095, 2011.
40. Westin JR, Fu S, Hong DS, Helgason T, Ouyang F, Angelo LS, Culotta KS, Westin SN, Kurzrock R. Validation of the phase 0 concept. J Clin Oncol 29:#TPS143, 2011.
41. Schlumbrecht MP, Xie S, Westin SN, Urbauer DL, Broaddus RR. Estrogen-induced gene expression predicts poor survival in high-grade serous carcinoma of the ovary. Gynecol Oncol 116:S163-4, 2010.
42. Schlumbrecht, MP, Sun CC, Westin SN, Zandstra F, Denton K, Rhodes H, Gonzales DG, Garcia EA, Levenback CL, Bodurka DC. Importance of lifestyle modification in cervical cancer survivors. J Clin Oncol 28:Abstr e15521), 2010.
43. Westin SN, Sun CC, Schlumbrecht MP, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Soliman PT, Lu KH, Bodurka DC. Persistant obesity among endometrial cancer survivors: A teachable moment?. Gynecol Oncol 116:S81, 2010.
44. Huang M, Burzawa JK, Djordjevic B, McCampbell A, Boyd-Rogers A, Meyer LA, Westin SN, Broaddus RR, Lu KH. Preinvasive disease in patients with Lynch Syndrome-associated endometrial cancer 116:S97, 2010.

Book Chapters

1. Bowser JL, Broaddus RR, Coleman RL, Westin SN. Endometrial Cancer. In: Targeted Therapy in Translational Cancer Research. Wiley. In Press. ISBN: 978-1-118-46857-9.
2. Westin SN, Meyer LA, Coleman RL. Ovarian Cancer. In: Targeted Therapy in Translational Cancer Research. Wiley. In Press. ISBN: 978-1-118-46857-9.
3. Bodurka DC, Westin SN, Sun CC. Gynecologic Cancer Survivorship Management. In: Advances in Cancer Survivorship Management, MD Anderson Cancer Care Series. Ed(s) Foxhall LE, Rodriguez MA. Springer: New York, 125-144, 2014. ISBN: 9781493909858.
4. Westin SN, Broaddus RR. Molecular Targeted Therapies in Endometrial Cancer. In: Endometrial Cancer: A Comprehensive Clinical and Translational Update. Ed(s) I Diaz-Padilla, J Garcia-Donas. Nova Science Pub Incorporated, 2014.
5. Djordjevic B, Westin SN, Broaddus RR. Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer. In: Molecular Oncology. Ed(s) JL Hunt, JR Goldblum. Elsevier: Philadelphia, Pa, 859-878, 2012.
6. Westin SN, Sood AK, Coleman RL. Targeted Therapy and Molecular Genetics. In: Clinical Gynecologic Oncology, 8th. Ed(s) PJ DiSaia, WT Creasman. Elsevier/Saunders: Philadelphia, PA, 539-560, 2012.

Letters to the Editor

1. Westin SN, Ramondetta L. Surgical removal of a gigantic abdominal mass: A multidisciplinary approach. Obstet Gynecol 118(3):710-1, 9/2011. PMID: 21860309.

Manuals, Teaching Aids, Other Teaching Publications

1. Holman L, Fu S, Westin SN(Contributor, Cervical, Endometrial & Ovarian Cancer). Handbook of Targeted Cancer Therapy. Ed(s) Karp DD, Falchook GS. Wolters Kluwer: Philadelphia, PA, 12/2014. PMID: 9781451193268.

Last updated: 5/24/2016